Evidence map›Paper›PMID 42569079›Full record

ArticleACS omega2026

The Application of Amoc Amino Acids in the Synthesis of Polypeptides.

Shuangchun Xiang, Feng Gao, Fengyun Tian, Congchong Liu, Furui Xiang, Guodong Shi, Yu Teng, Xiangyu Liu, Longhui Dong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shuangchun XiangAlpha Biopharmaceuticals Co., Ltd., No. 50th, LuanXiu Avenue, ChangXing Island Economic Zone, Dalian 116318, P. R. China.ORCID https://orcid.org/0009-0002-2714-9027
Feng GaoBeijing Mediking Biopharm Co., Ltd., 4/F, Bld.A, Courtyard A6, Yongchang Middle Road, Economic and Technical Development Zone, Beijing 100176, P. R. China.
Fengyun TianAlpha Biopharmaceuticals Co., Ltd., No. 50th, LuanXiu Avenue, ChangXing Island Economic Zone, Dalian 116318, P. R. China.
Congchong LiuAlpha Biopharmaceuticals Co., Ltd., No. 50th, LuanXiu Avenue, ChangXing Island Economic Zone, Dalian 116318, P. R. China.
Furui XiangFaculty of Science and Technology, Sophia University, 7-1 Kioicho, Chiyoda City, Tokyo 102-8554, Japan.
Guodong ShiAlpha Biopharmaceuticals Co., Ltd., No. 50th, LuanXiu Avenue, ChangXing Island Economic Zone, Dalian 116318, P. R. China.
Yu TengAlpha Biopharmaceuticals Co., Ltd., No. 50th, LuanXiu Avenue, ChangXing Island Economic Zone, Dalian 116318, P. R. China.
Xiangyu LiuAlpha Biopharmaceuticals Co., Ltd., No. 50th, LuanXiu Avenue, ChangXing Island Economic Zone, Dalian 116318, P. R. China.
Longhui DongShanghai Leju Biochem ltd., 605# 19, Building 238, Jiang Chang San Lu, Jintian, Shanghai 200436, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 2-alkanoyl-9-fluorenylmethoxycarbonyl (abbreviated as Amoc) protecting group was obtained by introducing an alkanoyl group onto Fmoc. By introducing an alkyl acyl group with a moderate electron-withdrawing ability at the 2-position of Fmoc, Amoc can be easily removed with a 0.5%-2% piperidine or piperazine solution, thereby avoiding many problems associated with the Fmoc strategy, enabling green peptide synthesis, and improving the quality of the crude product.

Identifiers

PMID42569079
PMCPMC13448930

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.